secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-07-16T20:35:25+00:00
Accession:  0001140361-26-028716
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics appoints three new directors to its board, effective August 1, 2026
--------------------------------------------------------------------------------

- Yue Xiong (CSO) appointed as Class I director; no additional compensation for board service.
- Maxwell Kirkby appointed as Class II director and to Compensation Committee; receives 40k stock options vesting over 3 years.
- Claire Weston appointed as Class III director and to Audit Committee; receives same option grant.
- Appointments expand board expertise in scientific, clinical development, and cross-border operations.
- Effective date August 1, 2026; terms expire at 2027, 2028, and 2029 annual meetings respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126028716/0001140361-26-028716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126028716/ef20078088_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-028716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer